NASDAQ:TRVI

Trevi Therapeutics Stock Forecast, Price & News

$2.23
-0.06 (-2.62 %)
(As of 06/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.20
$2.33
50-Day Range
$2.00
$2.70
52-Week Range
$1.94
$8.50
Volume37,950 shs
Average Volume76,530 shs
Market Capitalization$44.44 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.08
30 days | 90 days | 365 days | Advanced Chart
Receive TRVI News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Trevi Therapeutics logo

About Trevi Therapeutics

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation; and Rutgers to develop and commercialize products incorporating nalbuphine for any human or animal use. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.62 out of 5 stars

Medical Sector

430th out of 2,100 stocks

Pharmaceutical Preparations Industry

208th out of 832 stocks

Analyst Opinion: 3.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Trevi Therapeutics (NASDAQ:TRVI) Frequently Asked Questions

Is Trevi Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Trevi Therapeutics stock.
View analyst ratings for Trevi Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Trevi Therapeutics?

Wall Street analysts have given Trevi Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Trevi Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Trevi Therapeutics?

Trevi Therapeutics saw a increase in short interest in May. As of May 14th, there was short interest totaling 83,900 shares, an increase of 36.0% from the April 29th total of 61,700 shares. Based on an average daily volume of 47,800 shares, the days-to-cover ratio is currently 1.8 days. Currently, 1.4% of the company's shares are sold short.
View Trevi Therapeutics' Short Interest
.

When is Trevi Therapeutics' next earnings date?

Trevi Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Trevi Therapeutics
.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) issued its quarterly earnings data on Thursday, May, 13th. The company reported ($0.43) EPS for the quarter, beating the Zacks' consensus estimate of ($0.49) by $0.06.
View Trevi Therapeutics' earnings history
.

How has Trevi Therapeutics' stock price been impacted by Coronavirus?

Trevi Therapeutics' stock was trading at $3.18 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TRVI stock has decreased by 29.9% and is now trading at $2.23.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for TRVI?

4 brokerages have issued 12 month target prices for Trevi Therapeutics' stock. Their forecasts range from $9.00 to $13.00. On average, they expect Trevi Therapeutics' stock price to reach $11.00 in the next year. This suggests a possible upside of 393.3% from the stock's current price.
View analysts' price targets for Trevi Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Trevi Therapeutics' key executives?

Trevi Therapeutics' management team includes the following people:
  • Ms. Jennifer L. Good, Co-Founder, CEO, Pres, Principal Financial Officer & Director (Age 56, Pay $662.64k)
  • Dr. Thomas R. Sciascia, Co-Founder & Chief Medical Officer (Age 68, Pay $476.25k)
  • Mr. Christopher Galletta, Controller & Chief Accounting Officer (Age 43)
  • Dr. Amale Hawi, Sr. VP of CMC (Age 67)
  • Mr. Frank P. Muscolo, Exec. Officer (Age 64)
  • Dr. William P. Forbes Pharm.D., Pharm. D., Chief Devel. Officer (Age 59)

Who are some of Trevi Therapeutics' key competitors?

What other stocks do shareholders of Trevi Therapeutics own?

When did Trevi Therapeutics IPO?

(TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Trevi Therapeutics' stock symbol?

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

Who are Trevi Therapeutics' major shareholders?

Trevi Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.61%), WealthTrust Axiom LLC (0.19%), BlackRock Inc. (0.16%), Citadel Advisors LLC (0.05%) and Citadel Advisors LLC (0.05%).
View institutional ownership trends for Trevi Therapeutics
.

Which major investors are buying Trevi Therapeutics stock?

TRVI stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, WealthTrust Axiom LLC, Citadel Advisors LLC, Citadel Advisors LLC, and BlackRock Inc..
View insider buying and selling activity for Trevi Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Trevi Therapeutics?

Shares of TRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevi Therapeutics' stock price today?

One share of TRVI stock can currently be purchased for approximately $2.23.

How much money does Trevi Therapeutics make?

Trevi Therapeutics has a market capitalization of $44.44 million. The company earns $-32,760,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.

How many employees does Trevi Therapeutics have?

Trevi Therapeutics employs 23 workers across the globe.

What is Trevi Therapeutics' official website?

The official website for Trevi Therapeutics is www.trevitherapeutics.com.

Where are Trevi Therapeutics' headquarters?

Trevi Therapeutics is headquartered at 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510.

How can I contact Trevi Therapeutics?

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company can be reached via phone at 203-304-2499 or via email at [email protected]


This page was last updated on 6/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.